Kiwanis Club honors Deputy Miller for saving abused puppies
The Kiwanis Club of Joplin honored Newton County deputy Morgan Miller with this month's First Responder of the Month Award. The ceremony took place during this afternoon's meeting at the Joplin Elk's Lodge.
Miller was responsible for rescuing several puppies and their mother after responding to a report of animal abuse in March. Those puppies had zip ties around their throats.Not only did she rescue them—she contacted local shelters and raised funds to care for them.
'It's a little heartbreaking when you see puppies like that, especially when they can't voice, you know, how they're feeling. So, it's a little heartbreaking when you see somebody trying to kill dogs like that. I'm grateful that I was the one that responded and take care of those puppies,' Dep. Morgan Miller, NCSO.
'Hey, we're very proud of Morgan today. She went well above and beyond the expectations of anybody. We have high expectations of our deputies at the sheriff's department, and she went above that,' Joe Moore, NCSO Chief Deputy.
Most of Miller's work following the incident happened while she was off duty.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
10 minutes ago
- NBC News
New lawsuits accuse construction companies in deadly New York City outbreak of Legionnaires' disease
A pair of construction companies overlooked safety concerns, causing a 'completely preventable' outbreak of Legionnaires' disease in New York City that's killed at least five people and sickened dozens more, according to lawsuits filed on Wednesday. The Harlem outbreak has been traced back to July 26 with clusters in Upper Manhattan ZIP codes 10027, 10030, 10035, 10037 and 10039, officials said. "This medical tragedy that led to the deaths of five citizens from Harlem, that we know about, was a completely preventable outbreak," plaintiffs' attorney Ben Crump told reporters. "It was completely preventable. And so when corporations cut corners, tragedies like this happen, preventable tragedies, unnecessary tragedies, people being hospitalized for days and weeks, having issues that cause them permanent damage." Reps for the defendants, Skanska USA Building, Inc., and Rising Sun Construction LLC. could not be immediately reached for comment on Wednesday. Construction worker Duane Headley filed a complaint against Rising Sun, claiming he was sickened while working at a construction site at 506 Lenox Ave., near Harlem Hospital. Rising Sun allegedly "created and permitted a defective, dangerous and/or hazardous condition" where Headley was working, the lawsuit said. Headley survived the illness but remains hospitalized, lawyers said. Nunzio Quinto claims he was exposed to the Legionella bacteria while working at the New York City Public Health Laboratory Building, near Harlem Hospital, at 40 W. 137th St. Quinto, who is suing Skanska, said the defendant "breached its duty" to "timely remediate the Legionella colonization of the water distribution and/or cooling systems," according to his lawsuit. "I had no energy and unable to do anything," Quinto told reporters. "I'm finally starting to get up and walk around a little bit now and can do basic things." While the plaintiffs are seeking financial compensation for their medical costs, lost wages, pain and suffering, Quinto said he hopes these civil actions unearth reasons behind the outbreak. "But my thing is, I want answers to what's going on," said Quinto, alongside civil rights activists Crump and the Rev. Al Sharpton. "I can't have a safe place to work? This is New York City."
The Hill
2 hours ago
- The Hill
Stephen Miller blasts ‘stupid white hippies' protesting DC crackdown
Deputy White House chief of staff Stephen Miller on Wednesday railed against what he called 'stupid white hippies' who were protesting the federal crackdown on crime in the nation's capital and argued they did not represent the citizens of Washington, D.C. Miller, Vice President Vance and Defense Secretary Pete Hegseth visited Union Station on Wednesday, where National Guard troops have been stationed outside for days in a show of force near the transportation hub. 'We are not going to let the communists destroy a great American city, let alone the nation's capital,' Miller told the crowd near Shake Shack inside Union Station. 'And let's just also address another thing. All these demonstrators you've seen out here in recent days, all these elderly white hippies, they're not part of the city and never have been. And by the way, most of the citizens who live in Washington, D.C., are Black.' 'So we're going to ignore these stupid white hippies that all need to go home and take a nap because they're all over 90 years old,' he added. 'And we're going to get back to the business of protecting the American people and the citizens of Washington, D.C.' The Trump administration earlier this month began surging federal law enforcement across parts of the district to crack down on what the White House said was an unacceptable level of crime, despite statistics showing violent crime has declined in the city. Last week, Trump took federal control of the Metropolitan Police Department and deployed hundreds of National Guard troops across the city to further the crack down on crime. The White House has said officers across the district have made more than 550 arrests since the surge in federal resources began on Aug. 7. But local residents have largely expressed disapproval with the aggressive moves from the federal government. A Washington Post-Schar School poll of 604 D.C. residents published Wednesday found 65 percent do not think Trump's actions will make the city safer. Roughly 80 percent of residents said they opposed Trump's executive order to federalize the city's police department.
Yahoo
2 hours ago
- Yahoo
DexCom Expands Access and Innovation While Balancing Headwinds
DexCom, Inc. DXCM reported second-quarter 2025 results that highlighted robust top-line growth, continued progress in expanding access and meaningful product innovation. Revenues grew 15% year over year to $1.16 billion, with broad-based contributions from both the U.S. and international markets. Management raised full-year revenue guidance to $4.6-$4.625 billion, reflecting confidence in ongoing momentum, particularly in the type 2 non-insulin segment. At the same time, the company faces competitive pressures, regulatory uncertainties and operational hurdles, all of which affect the near-term risk-reward balance. With a leadership transition ahead, DexCom remains positioned for long-term expansion. DexCom share have gained 4% so far this year against the industry's decline of 7%. The S&P 500 Index increased 8.8% in that period. Image Source: Zacks Investment Research Short-Term Growth Drivers U.S. Expansion in Type 2 Non-Insulin Coverage: The most immediate growth catalyst is the rapid expansion of coverage for type 2 non-insulin patients. As of the second quarter, DexCom secured reimbursement with all three major U.S. PBMs, providing access to nearly 6 million covered lives. This development is already translating into strong new patient starts, reinforcing management's confidence in raising guidance. Importantly, clinicians are increasingly integrating CGM into earlier stages of care, accelerating adoption within primary care channels. Stelo Momentum and Consumer Adoption: DexCom's over-the-counter biosensor, Stelo, continues to gain traction. The app surpassed 400,000 downloads this summer, with rising adoption among wellness users and prediabetic populations. Partnerships with platforms like Oura and Amazon are broadening distribution and enhancing digital integration. While Stelo currently represents just 2-3% of revenues, it demonstrates the potential for DexCom to diversify beyond traditional diabetes management into broader metabolic health. 15-Day G7 Sensor Launch: FDA clearance for the 15-day G7 sensor marks another short-term catalyst. A potential launch in the rest of 2025 should support utilization and potentially improve gross margin dynamics as reimbursement negotiations shift toward monthly coverage models. This longer-wear sensor enhances convenience and strengthens DexCom's competitive positioning. Operational Improvements in Supply Chain: After supply constraints earlier in the year, DexCom restored inventory levels by executing record production months and leveraging expedited shipping. The company also rolled out a nationwide warranty program for pharmacy customers, bolstering service reliability. These operational stabilizations should mitigate near-term disruption risk and support smoother growth in the second half. Long-Term Growth Drivers Expanding International Coverage: International revenues grew 16% in the second quarter, led by DexCom ONE+ adoption. Coverage wins in regions such as Ontario, Canada, and France underscore growing global recognition of CGM's clinical and economic value. In markets like Japan and Germany, low penetration of basal insulin users presents a substantial long-term opportunity. Management expects further international expansion across both established and emerging markets to remain a durable growth pillar. Next-Generation G8 Platform and Multi-Analyte Sensing: Looking further, DexCom's G8 sensor platform represents the next major leap in CGM technology. Designed to be 50% smaller, with multi-analyte sensing capabilities, G8 could expand the addressable market by addressing broader metabolic monitoring needs, including ketone detection. While timelines depend on clinical and regulatory milestones, G8 is expected to reinforce DexCom's innovation leadership and strengthen competitive differentiation. Broader Clinical Applications: DexCom is also advancing evidence generation to expand CGM usage beyond diabetes. Recent clinical trials demonstrated benefits for gestational diabetes and type 2 non-insulin users, while early studies suggested positive outcomes in chronic kidney disease. As real-world evidence accumulates, these findings could pave the way for new reimbursement approvals and expanded adoption across metabolic health conditions. Software and AI Integration: DexCom continues to operate with a 'consumer technology mindset,' rolling out 17 app updates in the first half of 2025 alone. Innovations such as AI-enabled smart food logging, seamless integration with wearables like Oura, and enhanced data visualization enrich user experience and increase retention. These digital enhancements help transform CGM from a monitoring device into a comprehensive health platform, reinforcing customer loyalty and utilization. DXCM's Sales & EPS Estimates Image Source: Zacks Investment Research Challenges Margin Pressures and Inventory Costs: Despite revenue growth, gross margin contracted to 60.1% from 63.5% a year ago, largely due to higher logistics costs and expedited shipping. While management expects sequential improvement as supply-chain normalization continues, sustained investment in distribution and warranty programs may weigh on profitability in the near term. Competitive and Regulatory Uncertainty: DexCom faces intensifying competition, particularly from Abbott ABT, which is strengthening its integration with insulin pumps and advancing new sensor platforms. In addition, the CMS proposal for competitive bidding in CGM and pumps, while still preliminary, poses a medium-term risk. Medicare represents roughly 15% of DexCom's business, and any pricing compression could affect margins starting as early as 2027. Leadership Transition: CEO Kevin Sayer will step down in early 2026, handing leadership to current president Jake Leach. While Leach has been with DexCom since its inception and is well regarded, transitions of this magnitude always carry execution risk. Ensuring continuity of strategic focus, particularly across innovation and global expansion, will be critical. Conservative Guidance and Execution Risk: Although management raised revenue guidance, it remains cautious about the back half, citing the need to meet commitments despite outperformance in the first half. This conservatism reflects execution challenges around scaling new coverage wins, driving sustained utilization and balancing global expansion with profitability. Competition Update Abbott continues to assert dominant momentum, driven largely by its FreeStyle Libre portfolio. The company reported a strong 18.3 % increase in continuous glucose monitor sales in first-quarter 2025, boosting medical device revenues by 9.9 % — beating EPS forecasts for the 21st consecutive quarter. Underpinning its success, Abbott projects Libre franchise annual sales could reach $10 billion by 2028, fueling investor optimism around expanded CGM adoption. Roche RHHBY has maintained steady growth across its Diagnostics arm, achieving 6% sales growth in first quarter of 2025 on a constant-exchange-rate basis. Roche is advancing CGM technology, showcasing an AI-enabled SmartGuide system that predicts glucose trends and hypoglycemia up to two hours ahead. These innovations reinforce Roche's potential to integrate predictive analytics into diabetes care and expand its CGM footprint. Medtronic MDT is gaining traction with its Smart MDI and MiniMed 780G systems. Real-world data show that users of Medtronic's Smart MDI system achieved Time-in-Range averages of 67% to 71% when acting on insulin-alert prompts. Separately, use of the Medtronic's MiniMed 780G with SmartGuard improved HbA1C by 0.6% and increased Time-in-Range by nearly 10% versus manual insulin delivery. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Conclusion DexCom delivered another quarter of strong double-digit growth, underpinned by expanded access, international traction and product innovation. The company's leadership in CGM technology, coupled with growing evidence supporting broader use cases, provides a compelling long-term narrative. However, margin pressures, regulatory uncertainty, competitive threats and the looming CEO transition temper near-term enthusiasm. At current levels, the stock reflects both opportunity and risk in equal measure. Investors should continue to hold the stock and wait for greater clarity on execution in type 2 non-insulin adoption, international scale-up, and margin recovery before revisiting a more bullish outlook. DexCom currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
